[HTML][HTML] Predicting and interpreting large-scale mutagenesis data using analyses of protein stability and conservation
Understanding and predicting the functional consequences of single amino acid changes is
central in many areas of protein science. Here, we collect and analyze experimental …
central in many areas of protein science. Here, we collect and analyze experimental …
Preoperative endovascular embolization of meningiomas: update on therapeutic options
A Shah, O Choudhri, H Jung, G Li - Neurosurgical focus, 2015 - thejns.org
In this review paper the authors analyze new therapeutic options for the embolization of
meningiomas, as well as the future of meningioma treatment through recent relevant cohorts …
meningiomas, as well as the future of meningioma treatment through recent relevant cohorts …
Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review
T Graillon, D Romano, C Defilles, A Saveanu… - Journal of …, 2016 - thejns.org
OBJECTIVE Meningiomas express somatostatin receptor subtype 2 (SST2), which is
targeted by the somatostatin analog octreotide. However, to date, using somatostatin analog …
targeted by the somatostatin analog octreotide. However, to date, using somatostatin analog …
Understanding the origins of loss of protein function by analyzing the effects of thousands of variants on activity and abundance
M Cagiada, KE Johansson, A Valanciute… - Molecular Biology …, 2021 - academic.oup.com
Understanding and predicting how amino acid substitutions affect proteins are keys to our
basic understanding of protein function and evolution. Amino acid changes may affect …
basic understanding of protein function and evolution. Amino acid changes may affect …
Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease
Object The tumors most frequently associated with von Hippel-Lindau (VHL) disease are
hemangioblastomas. While they are associated with significant neurological impairment and …
hemangioblastomas. While they are associated with significant neurological impairment and …
Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation
M Miettinen, JK Killian, ZF Wang, J Lasota… - The American journal …, 2013 - journals.lww.com
Abstract A subset (7% to 10%) of gastric gastrointestinal stromal tumors (GISTs) is notable
for the immunohistochemical loss of succinate dehydrogenase (SDH) subunit B (SDHB) …
for the immunohistochemical loss of succinate dehydrogenase (SDH) subunit B (SDHB) …
[HTML][HTML] Human cytomegalovirus-encoded US9 targets MAVS and STING signaling to evade type I interferon immune responses
Human cytomegalovirus (HCMV) has evolved sophisticated immune evasion mechanisms
that target both the innate and adaptive immune responses. However, how HCMV encoded …
that target both the innate and adaptive immune responses. However, how HCMV encoded …
Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Mutations in genes encoding isocitrate dehydrogenases (IDH) 1 and 2 are common cancer-
related genetic abnormalities. Malignancies with mutated IDHs exhibit similar pathogenesis …
related genetic abnormalities. Malignancies with mutated IDHs exhibit similar pathogenesis …
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
MER Garcia-Rendueles, JC Ricarte-Filho, BR Untch… - Cancer discovery, 2015 - AACR
Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly
differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, is …
differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, is …
New syndrome of paraganglioma and somatostatinoma associated with polycythemia
Purpose The occurrence of≥ two distinct types of tumors, one of them paraganglioma
(PGL), is unusual in an individual patient, except in hereditary cancer syndromes. Patients …
(PGL), is unusual in an individual patient, except in hereditary cancer syndromes. Patients …